1 story in the last 7 days
The latest biogen news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks biogen across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Biogen agreed to acquire RayThera Inc. for up to $1 billion, adding multiple anti-inflammatory assets to its immunology pipeline. The lead candidate is expected to enter Phase 1 development in early Q3 2026. The deal includes an upfront payment and milestone-contingent payments.
Summaries by ByteBrief